SCHEDULE 13G/A: HBM Healthcare Investments Discloses 4.5% Passive Stake in Benitec Biopharma
Beneficial Ownership Disclosure
HBM Healthcare Investments (Cayman) Ltd. has filed an amended Schedule 13G, reporting a 4.5% passive beneficial ownership stake in Benitec Biopharma Inc. as of December 31, 2024.
Summary
- HBM Healthcare Investments (Cayman) Ltd. reported beneficial ownership of 1,041,669 shares of Benitec Biopharma Inc. Common Stock.
- This ownership represents approximately 4.5% of the outstanding Common Stock of Benitec Biopharma Inc.
- The percentage is calculated based on 23,216,425 shares of Common Stock outstanding as of November 12, 2024, as reported in Benitec Biopharma's Quarterly Report on Form 10-Q filed on November 14, 2024.
- The filing is an Amendment No. 2 to Schedule 13G, indicating an update to a previously filed statement.
- HBM Healthcare Investments (Cayman) Ltd. holds sole voting and sole dispositive power over the 1,041,669 shares.
- The Reporting Person certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine disclosure of beneficial ownership, indicating a passive investment below the 5% threshold. It does not contain information that would significantly alter sentiment positively or negatively about the issuer's operational performance or future prospects.
Future Outlook
This document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of a passive investment stake by a healthcare-focused investment firm in a biopharma company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant passive investor's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 11/12/2024 | Date as of which 23,216,425 shares of Common Stock were reported outstanding by the Issuer. |
| 11/14/2024 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 12/31/2024 | Date of event which requires the filing of this statement (ownership snapshot). |
| 02/13/2025 | Date the Schedule 13G was signed by HBM Healthcare Investments (Cayman) Ltd. |
Keywords
Benitec Biopharma, HBM Healthcare Investments, Schedule 13G, beneficial ownership, common stock, biopharma, investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.